Published online September 28, 2009
PEDIATRICS Vol. 124 No. 4 October 2009, pp. e662-e670 (doi:10.1542/peds.2009-0442)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Google Scholar
Right arrow Articles by Pawluski, J. L.
Right arrow Articles by Oberlander, T. F.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pawluski, J. L.
Right arrow Articles by Oberlander, T. F.
Related Collections
Right arrow Therapeutics & Toxicology
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

ARTICLE

Neonatal S100B Protein Levels After Prenatal Exposure to Selective Serotonin Reuptake Inhibitors

Jodi L. Pawluski, PhDa, Liisa A.M. Galea, PhDa,b, Ursula Brain, BAa, Michael Papsdorf, PhDa and Tim F. Oberlander, MDa,c

Departments of a Pediatrics
b Psychology, University of British Columbia, Vancouver, Canada
c BC Children's Hospital, Vancouver, Canada

OBJECTIVE: This study investigated neonatal S100B levels as a biomarker of prenatal selective serotonin reuptake inhibitor (SSRI) exposure.

METHODS: Maternal (delivery; N = 53) and neonatal (cord; N = 52) serum S100B levels were compared between prenatally SSRI-exposed (maternal, N = 36; neonatal, N = 37; duration: 230 ± 71 days) and nonexposed (maternal, N = 17; neonatal, N = 15) groups. Measures of maternal depression and anxiety symptoms were assessed during the third trimester (33–36 weeks), and neonatal outcomes, including Apgar scores, birth weight, gestational age at birth, and symptoms of poor neonatal adaptation, were recorded.

RESULTS: S100B levels were significantly lower in prenatally SSRI-exposed neonates than in nonexposed neonates, controlling for gestational age and third-trimester maternal mood (P = .036). In contrast, SSRI-exposed mothers had significantly higher maternal serum S100B levels, compared with nonexposed mothers (P = .014), even controlling for maternal mood in the third trimester. S100B levels were not associated with maternal or neonatal drug levels, duration of prenatal exposure, demographic variables, or risk for poor neonatal adaptation.

CONCLUSIONS: Prenatal SSRI exposure was associated with decreased neonatal serum S100B levels, controlling for prenatal maternal mood. Neonatal S100B levels did not reflect neonatal behavioral outcomes and were not related to pharmacologic indices. These findings are consistent with prenatal alcohol and cocaine exposures, which also alter central serotonin levels.

Key Words: mood • depression • anxiety • pregnancy • antidepressant • neonate • infant • mother • serotonin • medication

Abbreviations: SSRI—selective serotonin reuptake inhibitor • HAM-D—Hamilton Rating Scale for Depression • HAM-A—Hamilton Rating Scale for Anxiety • EPDS—Edinburgh Postnatal Depression Scale

Accepted Apr 16, 2009.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?